LBF22209PG13: Difference between revisions
No edit summary |
No edit summary |
||
| (9 intermediate revisions by 2 users not shown) | |||
| Line 6: | Line 6: | ||
|LipidBank=XPR1791 | |LipidBank=XPR1791 | ||
|LipidMaps=LMFA03010120 | |LipidMaps=LMFA03010120 | ||
|SysName= | |SysName=(9alpha,11alpha,15S) -Trihydroxy-20alpha,20beta-dihomoprosta- (cis-5,trans-13) -dien-1-oic acid | ||
|Common Name=&&20-ethyl Prostaglandin | |Common Name=&&20-ethyl Prostaglandin F_2 alpha&&(9alpha,11alpha,15S) -Trihydroxy-20alpha,20beta-dihomoprosta- (5Z,13E) -dien-1-oic acid&& | ||
|Source= | |Source= | ||
|Chemical Synthesis= | |Chemical Synthesis= | ||
|Metabolism= | |Metabolism= | ||
|Biological Activity=20-ethyl PGF2 | |Biological Activity=20-ethyl PGF2 alpha is considered as an intraocular hypotensive agent compared to unoprostone, due to the natural15(S) allylic hydroxyl in the lower side chain. | ||
}} | }} | ||
{{Lipid/Footer}} | {{Lipid/Footer}} | ||
Latest revision as of 18:05, 21 October 2010
| LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
| IDs and Links | |
|---|---|
| LipidBank | XPR1791 |
| LipidMaps | LMFA03010120 |
| CAS | |
| KEGG | {{{KEGG}}} |
| KNApSAcK | {{{KNApSAcK}}} |
| mol | LBF22209PG13 |
| 20-ethyl Prostaglandin F2α | |
|---|---|
| |
| Structural Information | |
| (9α,11α,15S) -Trihydroxy-20α,20β-dihomoprosta- (cis-5,trans-13) -dien-1-oic acid | |
| |
| Formula | C22H38O5 |
| Exact Mass | 382.271924326 |
| Average Mass | 382.53412000000003 |
| SMILES | C(CC[C@@H](C=C[C@H]([C@H]1CC=CCCCC(O)=O)[C@@H](C[C@H](O)1)O)O)CCCC |
| Physicochemical Information | |
| 20-ethyl PGF2 alpha is considered as an intraocular hypotensive agent compared to unoprostone, due to the natural15(S) allylic hydroxyl in the lower side chain. | |
| Spectral Information | |
| Mass Spectra | |
| UV Spectra | |
| IR Spectra | |
| NMR Spectra | |
| Other Spectra | |
| Chromatograms | |
